Generex Appoints Dr. Douglas Powell as Director of Immunobiology
Monday February 9, 10:51 am ET
Former Senior Scientist at Millennium Pharmaceuticals to Lead Development of Cancer and Infectious Disease Programs at Company's Subsidiary
[Should we understand this to mean that Millennium has decided to stop their HIV-program(s)? Not that I knew that there was one.]
TORONTO, Feb. 9 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News), announced today the appointment of Douglas Powell, Ph. D., formerly a Senior Scientist at Millennium Pharmaceuticals, Inc., to be Director of Immunobiology at Antigen Express, its immunomedicines subsidiary near Boston. Dr. Powell will coordinate development of novel T helper cell vaccine technologies in human T lymphocytes and dendritic cells for treatment of cancer and infectious diseases, and to combat bioterrorism agents.
Anna Gluskin, President & Chief Executive Officer of Generex, said, "We are pleased to have Dr. Powell join our scientific team. His substantial accomplishments, and well-deserved reputation as a creative and productive biotech inventor, participating in about 100 patent applications, position him for similarly great achievements with us."
"I am excited to join this very strong Antigen Express-Generex product development team," said Dr. Powell. "I have been impressed by the technology and believe we are well positioned to capitalize on large markets for unmet medical needs."
While at Millennium, Dr. Powell was the Principal Investigator in charge of the HIV program utilizing gene arrays to identify cellular targets for therapeutic intervention. He led the filing of 60 patents on methods and compositions for treating AIDS and HIV-related disorders. He also established multiple collaborative research programs with investigators at Harvard and Emory Universities, The University California, Irvine and The University Hospital Zurich, Switzerland.
biz.yahoo.com |
